Related Experiment Video

Updated: May 10, 2026

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation
08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

Mechanisms of endocrine resistance in breast cancer

C Kent Osborne1, Rachel Schiff

  • 1Dan L. Duncan Cancer Center, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA. kosborne@bcm.edu

Annual Review of Medicine
|October 5, 2010
PubMed

Insights

Blocking the estrogen receptor (ER) pathway is key in breast cancer treatment. Combining ER blockers with growth factor pathway inhibitors shows promise but requires better patient selection for optimal outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Endocrinology

Background:

  • The estrogen receptor (ER) pathway is crucial in breast cancer.
  • Endocrine therapy targeting ER is effective but faces resistance.
  • Resistance mechanisms include ER pathway deregulation and escape pathways.

Purpose of the Study:

  • To investigate the role of growth factor receptor pathways in endocrine resistance.
  • To evaluate combination therapies targeting ER and growth factor signaling.
  • To identify patient subgroups benefiting from cotargeting strategies.

Main Methods:

  • Preclinical models evaluating combined ER and growth factor receptor pathway inhibition.
  • Analysis of clinical studies on combination therapies.
  • Exploration of biomarkers for patient stratification.

Main Results:

  • Growth factor receptor pathways, like EGFR/HER2, are linked to endocrine resistance.
  • Combination therapies show preclinical efficacy by blocking crosstalk.
  • Clinical results partially support combination strategies, indicating a need for better patient selection.

Conclusions:

  • Targeting both ER and growth factor receptor pathways can overcome endocrine resistance.
  • Identifying patients likely to benefit from cotargeting is essential for clinical success.
  • Further research is needed to refine patient selection for combination therapies.

More Related Videos

Generation of Organ-conditioned Media and Applications for Studying Organ-specific Influences on Breast Cancer Metastatic Behavior09:44

Generation of Organ-conditioned Media and Applications for Studying Organ-specific Influences on Breast Cancer Metastatic Behavior

Published on: June 13, 2016

A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer07:35

A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer

Published on: December 26, 2016

Related Concept Videos

Endocrine Signaling01:45

Endocrine Signaling

Endocrine cells produce hormones to communicate with remote target cells found in other organs. The hormone reaches these distant areas using the circulatory system. This exposes the whole organism to the hormone but only those cells expressing hormone receptors or target cells are affected. Thus, endocrine signaling induces slow responses from its target cells but these effects also last longer.
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...